Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group. 1990

W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
April 1983, European journal of cancer & clinical oncology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
January 1988, Progress in clinical and biological research,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
September 1985, European journal of cancer & clinical oncology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
December 1989, European journal of cancer & clinical oncology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
February 1992, Seminars in urology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
October 1984, European journal of cancer & clinical oncology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
August 1989, European journal of cancer & clinical oncology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
December 1986, European journal of cancer & clinical oncology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
January 1998, European urology,
W G Jones, and S D Fosså, and A C Verbaeys, and J P Droz, and J G Klijn, and E Boven, and M de Pauw, and R Sylvester
October 1997, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!